Abstract
Future Medicinal ChemistryVol. 4, No. 8 EditorialFrom isolated hypotheses to connected practical studies: statisticians’ role in a seamless targeted therapy developmentQian Shi & Daniel J SargentQian ShiDepartment of Health Science Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USASearch for more papers by this author & Daniel J Sargent* Author for correspondenceDepartment of Health Science Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Search for more papers by this authorEmail the corresponding author at sargent.daniel@mayo.eduPublished Online:1 Jun 2012https://doi.org/10.4155/fmc.12.42AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: data analysisdata managementoncology researchstudy designtargeted therapyReferences1 Generali D, Berruti A, Foroni C et al. Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinic trial design. J. Natl Cancer Inst. Monogr.43,67–70 (2011).Crossref, CAS, Google Scholar2 Tajik P, Bossuyt PM. Genomic markers to tailor treatments: waiting or initiating? Hum. Genet.130,15–18 (2011).Crossref, Medline, Google Scholar3 Piantadosi S. Clinical Trials: a Methodologic Perspective. John Wiley & Sons, Inc., New York, NY, USA (1997).Google Scholar4 Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. Biomarkers and surrogate end points – the challenge of statistical validation. Clin. Oncol.7,309–317 (2010).Google Scholar5 Shi Q, Mandrekar SJ, Sargent DJ. Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials. Scand. J. Gastroenterol.47,356–362 (2012).Crossref, Medline, CAS, Google Scholar6 Abrams J, Erwin R, Eyfe G, Schilsky RL. Data submission standards and evidence requirements. Oncologist15,488–491 (2010)Crossref, Medline, Google Scholar7 Gallant GJA. Are the large pharmaceutical and biotechnology companies driving the discovery, research and development of targeted cancer therapies? Future Med. Chem.4,13–17 (2012).Link, CAS, Google ScholarFiguresReferencesRelatedDetailsCited By“Nomen Omen”: Exploring Connected Healthcare through the Perspective of Name Omen23 March 2020 | Healthcare, Vol. 8, No. 1 Vol. 4, No. 8 Follow us on social media for the latest updates Metrics Downloaded 91 times History Published online 1 June 2012 Published in print May 2012 Information© Future Science LtdKeywordsdata analysisdata managementoncology researchstudy designtargeted therapyFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
